The role of BDNF, NTRK2 gene and their interaction in development of treatment-resistant depression: Data from multicenter, prospective, longitudinal clinic practice
Authors:
- 1 January 2013
- journal article
- research article
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 47 (1) , 8-14
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Venlafaxine inhibits the upregulation of plasma tumor necrosis factor-alpha (TNF-α) in the Chinese patients with major depressive disorder: A prospective longitudinal studyPsychoneuroendocrinology, 2013
- Vulnerability to Depression: From Brain Neuroplasticity to Identification of BiomarkersJournal of Neuroscience, 2011
- Therapeutic options in treatment-resistant depressionAnnals of Medicine, 2011
- Antidepressant effects, of magnetic seizure therapy and electroconvulsive therapy, in treatment-resistant depressionJournal of Psychiatric Research, 2011
- Integrating common and rare genetic variation in diverse human populationsNature, 2010
- Comparisons of the Efficacy and Tolerability of Extended-Release Venlafaxine, Mirtazapine, and Paroxetine in Treatment-Resistant DepressionJournal of Clinical Psychopharmacology, 2010
- Association of Brain-Derived Neurotrophic Factor Genetic Val66Met Polymorphism with Severity of Depression, Efficacy of Fluoxetine and Its Side Effects in Chinese Major Depressive PatientsNeuropsychobiology, 2009
- Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depressionJournal of Psychopharmacology, 2009
- Genome-wide association study of bipolar disorder in European American and African American individualsMolecular Psychiatry, 2009
- The BDNF val66met Polymorphism Affects Activity-Dependent Secretion of BDNF and Human Memory and Hippocampal FunctionCell, 2003